BioCentury
ARTICLE | Strategy

Leftovers in Enzon's refrigerator

November 16, 2009 8:00 AM UTC

Now that activist shareholders have won their two-year battle to restructure Enzon Pharmaceuticals Inc., the question is what will happen to the development stage assets that remain.

Last week, the company announced it will sell its specialty pharma business to Sigma-Tau S.p.A. The deal includes Enzon's four marketed products: Oncaspar pegaspargase for acute lymphoblastic leukemia (ALL); Adagen enzyme replacement therapy for severe combined immunodeficiency disease (SCID); DepoCyt Ara-C for lymphomatous meningitis; and Abelcet amphotericin B for fungal infections. Sigma-Tau also gains Enzon's Indianapolis, Ind., manufacturing facility...